86
Participants
Start Date
May 31, 2008
Primary Completion Date
July 31, 2011
Study Completion Date
July 31, 2011
Ezatiostat Hydrochloride
"Dose Schedule 1-3000 mg orally per day in two divided doses for two weeks followed by 1 week with no treatment per three week cycle.~Dose Schedule 2-2000 mg orally per day in two divided doses for three weeks followed by 1 week with no treatment per four week cycle."
St. Vincent's Comprehensive Cancer Center, New York
University of Rochester Medical Center, Rochester
Center for Cancer and Blood Disorders, Bethesda
Suburban Hematology-Oncology Associates, P.C., Lawrenceville
Northeast Georgia Cancer Care, LLC, Athens
The Center for Hematology Oncology, Boca Raton
Moffitt Cancer Center, Tampa
Lakeland Regional Cancer Center, Lakeland
Case Western Reserve University/University Hospitals of Cleveland, Cleveland
Hematology & Medical Oncology, Cleveland
Central Hematology Oncology Medical Group, Inc., Terre Haute
Loyola University Chicago, Maywood
Joliet Oncology-Hematology Associates, Ltd., Joliet
Southern Illinois University School of Medicine, Springfield
The University of Oklahoma Health Sciences Center, Oklahoma City
Cancer Care Associates, Oklahoma City
Cancer Care Associates, Tulsa
MD Anderson Cancer Center, Houston
Cancer Care Centers of South Texas, San Antonio
University of Colorado at Denver Health Sciences Center, Aurora
Comprehensive Cancer Centers of Nevada, Henderson
UCLA Medical Center, Los Angeles
Clinical Trials and Research Associates, Inc., Montebello
North Valley Hematology/Oncology Medical Group, Northridge
Wilshire Oncology Medical Group, Inc., La Verne
Central Hematology Oncology Medical Group, Inc., Alhambra
Cancer Care Associates Medical Group, Inc., Redondo Beach
Desert Hematology Oncology Medical Group, Rancho Mirage
St. Jude Heritage Healthcare, Fullerton
Sansum Clinic, Santa Barbara
Santa Barbara Hematology Medical Group, Inc., Santa Barbara
Central Coast Medical Oncology Corporation, Santa Maria
Bay Area Cancer Research Group, Pleasant Hill
Kaiser Permanente, Portland
Arizona Cancer Center, Tucson
Cancer Institute of New Jersey, New Brunswick
Lead Sponsor
Telik
INDUSTRY